Overview

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Status:
RECRUITING

Trial end date:
2027-04-07

Target enrollment:

Participant gender:

Summary

An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.

Phase:

PHASE1

Details

Lead Sponsor:

Ting Deng

Collaborator:

Neowise Biotechnology